## **CLAIMS**

1. A process for the preparation of a compound of formula (I)

which comprises hydrolysis of a compound of formula (II)

5

$$SO_2$$
 $N$ 
 $COCH_3$ 
(II)

- 2. A process according to Claim 1 which is carried out under basic conditions.
- 3. A process according to Claim 2 wherein said hydrolysis is performed using potassium carbonate in methanol/water.
- 4. A process according to Claim 1 wherein the compound of formula (II) is obtained by catalytic reduction of a compound of formula (III)

5. A process according to Claim 4 wherein said reduction is carried out using hydrogen or a hydrogen source in the presence of a suitable catalyst.

15

- 6. A process according to Claim 5 wherein said reduction is carried out using hydrogen at a pressure of from 1 to 15 atmospheres.
- 7. A process according to Claim 5 wherein said reduction is carried out using a hydrogen source which is ammonium formate or formic acid.

- 8. A process according to according to Claim 4 wherein said catalyst is palladium on carbon, Raney nickel, platinum oxide, rhodium, or ruthenium.
- 9. A process according to Claim 8 wherein said catalyst is 5% w/w palladium on 5 carbon.
  - 10. A process according to Claim 4 wherein the catalytic reduction is carried out in the presence of an acid.
  - 11. A process according to Claim 10 wherein said acid is methanesulphonic acid, acetic acid, or trifluoroacetic acid.
  - 12. A process according to Claim 4 wherein the compound of formula (II) obtained by catalytic reduction is slurried with cold aqueous tetrahydrofuran before hydrolysis to the compound of formula (I).
    - 13. A process according to Claim 4 wherein the compound of formula (III) is obtained by treating a compound of formula (IV)

15

20

25

10

with phenyl vinyl sulphone in the presence of a palladium catalyst, a triarylphosphine and a base.

- 14. A process according to Claim 13 wherein the compound of formula (IV) is obtained by N-acetylating (R)-5-bromo-3-(N-methylpyrrolidin-2-ylmethyl)
  1H-indole.
- 15. A process according to Claim 1 wherein the compound of formula (I) so obtained is converted to a pharmaceutically acceptable acid addition salt by treatment with an appropriate acid.
- 16. A process according to Claim 15 wherein said conversion is carried out *in situ* without isolation of the compound of formula (I).
  - 17. A process according to Claim 15 wherein the acid is hydrobromic acid and the resulting salt is the hydrobromide.
    - 18. The compound of formula (II):

19. Eletriptan which is substantially free of

20. A pharmaceutically acceptable acid addition salt of eletriptan which is substantially free of

- 21. A pharmaceutically acceptable acid addition salt of eletriptan according to Claim 20 which is the hydrobromide.
- A pharmaceutical composition comprising eletriptan or a pharmaceutically
   acceptable acid addition salt thereof which is substantially free of

and a suitable carrier or excipient.

23. A composition according to Claim 22 wherein said pharmaceutically acceptable acid addition salt is the hydrobromide.